1/30
08:14 am
biib
Biogen (NASDAQ:BIIB) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Low
Report
Biogen (NASDAQ:BIIB) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
1/28
09:07 am
biib
Lupus Research Alliance Applauds U.S. FDA Breakthrough Therapy Designation for Litifilimab in Cutaneous Lupus Erythematosus [Yahoo! Finance]
Low
Report
Lupus Research Alliance Applauds U.S. FDA Breakthrough Therapy Designation for Litifilimab in Cutaneous Lupus Erythematosus [Yahoo! Finance]
1/28
07:30 am
biib
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
Low
Report
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
1/27
07:19 am
biib
Biogen (NASDAQ:BIIB) had its "neutral" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Biogen (NASDAQ:BIIB) had its "neutral" rating reaffirmed by analysts at Citigroup Inc..
1/25
06:42 pm
biib
FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review [Yahoo! Finance]
Low
Report
FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review [Yahoo! Finance]
1/25
06:30 pm
biib
FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
Low
Report
FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
1/23
09:17 am
biib
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Wedbush from $143.00 to $178.00. They now have a "neutral" rating on the stock.
Low
Report
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Wedbush from $143.00 to $178.00. They now have a "neutral" rating on the stock.
1/21
04:37 pm
biib
3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026 [Yahoo! Finance]
Low
Report
3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026 [Yahoo! Finance]
1/15
04:23 pm
biib
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Mizuho from $177.00 to $207.00. They now have an "outperform" rating on the stock.
Low
Report
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Mizuho from $177.00 to $207.00. They now have an "outperform" rating on the stock.
1/15
04:23 pm
biib
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Sanford C. Bernstein from $157.00 to $197.00. They now have a "market perform" rating on the stock.
Low
Report
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Sanford C. Bernstein from $157.00 to $197.00. They now have a "market perform" rating on the stock.
1/15
10:24 am
biib
Biogen: Why I Anticipate A Difficult 2026 For 'End Of An Era' Pharma [Seeking Alpha]
Low
Report
Biogen: Why I Anticipate A Difficult 2026 For 'End Of An Era' Pharma [Seeking Alpha]
1/13
06:04 pm
biib
Biogen (NASDAQ:BIIB) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Medium
Report
Biogen (NASDAQ:BIIB) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
1/12
11:05 am
biib
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
Low
Report
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
1/10
03:22 pm
biib
Here's What Analysts Think About Biogen Inc. (BIIB) [Yahoo! Finance]
Low
Report
Here's What Analysts Think About Biogen Inc. (BIIB) [Yahoo! Finance]
1/8
10:04 am
biib
Biogen (NASDAQ:BIIB) was given a new $190.00 price target on by analysts at Truist Financial Corporation.
Low
Report
Biogen (NASDAQ:BIIB) was given a new $190.00 price target on by analysts at Truist Financial Corporation.
1/8
08:42 am
biib
Biogen (NASDAQ:BIIB) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Low
Report
Biogen (NASDAQ:BIIB) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
1/7
07:08 am
biib
Biogen (NASDAQ:BIIB) had its "neutral" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Biogen (NASDAQ:BIIB) had its "neutral" rating reaffirmed by analysts at Citigroup Inc..
1/6
07:01 pm
biib
Biogen (NASDAQ:BIIB) was given a new $185.00 price target on by analysts at UBS Group AG.
Low
Report
Biogen (NASDAQ:BIIB) was given a new $185.00 price target on by analysts at UBS Group AG.
1/5
10:07 pm
biib
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China [Yahoo! Finance]
Medium
Report
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China [Yahoo! Finance]
12/30
09:01 am
biib
Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge [Seeking Alpha]
Low
Report
Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge [Seeking Alpha]
12/22
11:50 am
biib
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS [Yahoo! Finance]
Low
Report
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS [Yahoo! Finance]
12/22
11:20 am
biib
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
Low
Report
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
12/19
09:18 am
biib
Biogen (NASDAQ:BIIB) had its price target raised by analysts at BMO Capital Markets from $150.00 to $165.00. They now have a "market perform" rating on the stock.
Medium
Report
Biogen (NASDAQ:BIIB) had its price target raised by analysts at BMO Capital Markets from $150.00 to $165.00. They now have a "market perform" rating on the stock.
12/19
05:24 am
biib
HSBC Downgrades Biogen Inc. (BIIB) to Reduce Despite Pipeline Progress [Yahoo! Finance]
Medium
Report
HSBC Downgrades Biogen Inc. (BIIB) to Reduce Despite Pipeline Progress [Yahoo! Finance]
12/12
12:01 pm
biib
Biogen (NASDAQ:BIIB) was given a new $156.00 price target on by analysts at Morgan Stanley.
Low
Report
Biogen (NASDAQ:BIIB) was given a new $156.00 price target on by analysts at Morgan Stanley.